2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Reliance Global Group, Inc. (EZRA) closed its acquisition of the Oblivus GPU cloud computing platform on November 3, 2026, paying $3,000,000 in cash at closing from cash on hand, with up to $750,000 more in milestone payments that depend on future revenue. The company says Oblivus generated about $1.5 million in revenue for the twelve months ended September 2026, based on unaudited seller records, and that the deal marks its entry into the AI infrastructure market. Shareholders should note that the company has not yet filed the required acquired-business financial statements and pro forma information, and that its trading symbol is set to change to XGPU on November 10, 2026.
Closing payment of $3,000,000 in cash; up to two $375,000 milestone payments tied to average monthly cash revenue of $79,000 and $120,000
Oblivus reported about $1.5 million in revenue for the twelve months ended September 2026, per seller's unaudited records
Consulting agreement with founder Matthew Antoun: $250,000 in cash fees over 12 months, plus stock up to $600,000 subject to Board approval
Trading symbol expected to change from EZRA to XGPU on Nasdaq at the open on November 10, 2026
DoubleVerify said it expects the merger under its August 6, 2026 agreement to close in the fourth quarter of 2026, subject to remaining closing conditions. Under the merger, DoubleVerify will survive as a wholly owned subsidiary of Neptune BidCo US Inc., so shareholders will be affected by the completion timing and terms of the deal.
Merger Agreement dated August 6, 2026, with Neptune BidCo US Inc. (Parent) and Wallace Merger Sub Inc. (Merger Sub)
Company expects closing during the fourth quarter of 2026, subject to satisfaction or waiver of remaining conditions
After the merger, DoubleVerify continues as the surviving corporation and a wholly owned subsidiary of Parent
Filing is made under Regulation FD and restates terms of a previously announced transaction
JBS N.V. agreed to acquire Flora Produtos de Higiene e Limpeza S.A., a Brazilian personal care and household products company, from its controlling shareholder J&F, in a transaction valued at US$542 million including assumed debt. JBS also agreed to buy Canal Rural, a Brazilian agribusiness media company, for R$88.1 million, and both deals are related-party transactions to be paid mainly in JBS Class A shares, which would add to the share count and dilute existing holders.
Flora: R$2.968 billion purchase price (US$542 million enterprise value); equity consideration of US$367 million to be paid in JBS Class A shares and/or BDRs
Canal Rural: R$88.1 million purchase price, paid to J&F in Class A shares; the Ex-99.1 release gives a US$11 million transaction value
Share issuance is based on a reference price of R$66.82916 per share (US$12.20 30-day volume-weighted average), with about 31.4 million treasury shares, or 2.9% of the share count, cited in the market presentation
Both agreements were signed November 9, 2026, and the transactions are expected to close in December 2026, subject to customary closing conditions
QXO Chairman and CEO Brad Jacobs said on a November 9, 2026 conference call that September sales were much stronger than expected and that the company pre-released third-quarter adjusted EBITDA of $557 million on revenue of $4.9 billion, an 11.4% margin. He also said his family office will lead a $1 billion cash investment in NYSE American-listed CKX Lands, under which he would own a majority stake and become its chairman and CEO while remaining QXO's chairman and CEO.
Preliminary Q3 adjusted EBITDA of $557 million on revenue of $4.9 billion, an adjusted EBITDA margin of 11.4%
Companywide pricing improved 2.2% year-over-year in Q3; daily sales rose 5.4% year-over-year across the company in October
$1 billion CKX investment: $900 million from Jacobs Private Equity and $100 million from co-investors led by Heritage Partners, with CKX stockholder approval still required
Long-term target of $4 billion adjusted EBITDA by 2030 before additional acquisitions, versus roughly $1.75 billion in current consensus estimates
Forge Nano Holdings said it completed its merger with HzO, Inc. on November 4, 2026, with HzO surviving as a wholly owned subsidiary. HzO stockholders were issued Forge Nano common stock as consideration, and part of that stock is held back for twelve months to secure post-closing adjustments and indemnification. The filing adds dilution from the new shares, but it does not provide HzO financial results or the effect on Forge Nano's earnings.
Merger consideration is based on a $55.0 million base purchase price, plus or minus closing cash, working capital, indebtedness and expense adjustments, divided by $10.00 per share.
Forge Nano issued 5,772,645 shares at the Effective Time, with 1,533,795 Holdback Shares held back for twelve months.
Shares received by HzO stockholders are locked up until the earlier of six months after the Effective Time or when the stock closes at or above $12.00 for 20 of 30 trading days.
HzO's CFO Jason Savod and President and COO Rachael Lerebours signed employment agreements with Forge Nano effective after the Effective Time.
Valor Energy entered an amendment to its equity transfer agreement with Glorious Star, LLC for the Youngstown Computing Center, changing how the $360,000 deposit is handled and setting a closing deadline. The filing states the remaining purchase price is payable at closing and that any additional power capacity would be a separate transaction requiring its own agreement, which does not affect the closing obligations.
Purchase price is $3,600,000; the $360,000 deposit is now paid directly to the seller after Valor confirms due diligence and its Initial Valuation are satisfactory, replacing escrow
Payment is a generally non-refundable down payment credited toward the price, subject to refund provisions in the amendment
Closing is due by the thirtieth Business Day after the original October 18, 2026 effective date, unless extended in writing
Amendment dated November 3, 2026; filed November 9, 2026 as Exhibit 10.1
Surgery Partners reported third-quarter 2026 revenue down 0.8% to $815.3 million, with a net loss attributable to the company of $21.1 million and Adjusted EBITDA of $132.7 million. The same day, it amended its pending merger agreement with HealthSpan Partners to raise the cash consideration to $25.00 per share, and it will no longer provide guidance or hold an earnings call, which matters to shareholders because the deal price and timing now drive the stock's outlook.
Q3 2026 revenue was $815.3 million, down from $821.5 million a year earlier; same-facility revenues rose 6.0%.
Net loss attributable to Surgery Partners was $21.1 million, or $0.16 per share, versus a loss of $22.7 million, or $0.18 per share, in Q3 2025.
The amended HealthSpan merger sets consideration at $25.00 per share in cash, an enterprise value of up to about $6.0 billion, and is still expected to close in Q1 2027.
The amendment adds a Ticking Fee of 10% per annum on $25.00 per share if stockholder approval is obtained but the merger has not closed by March 1, 2027.
ZeroStack Corp. agreed on November 3, 2026 to sell all outstanding shares of its wholly owned subsidiary Phatebo GmbH to New Horizon Pharma B.V. for an aggregate price of €2,150,000. Closing depends on German foreign direct investment clearance and other agreed closing conditions, so the sale is not yet complete. The filing does not state the effect of the sale on ZeroStack's financial results.
Buyer: New Horizon Pharma B.V.; the company owns 100% of Phatebo GmbH before the sale.
Aggregate purchase price: €2,150,000.
Closing requires German foreign direct investment clearance and other closing conditions in the Purchase Agreement.
Purchase Agreement dated November 3, 2026 is filed as Exhibit 10.1.
Park Dental Partners closed its acquisition of the dental services organization supporting Village Family Dental on November 6, 2026, expanding into North Carolina, its fourth state. Base consideration was approximately $39.1 million, including 474,535 restricted shares valued at about $9.2 million, with potential aggregate consideration of up to about $46.0 million including earnouts. The company said the transaction's financial impact, including on 2026 guidance, will be shared with its earnings release on November 12, 2026.
Closed November 6, 2026; the transaction was first disclosed August 10, 2026, and adds 12 practice locations and 47 doctors.
Base consideration of approximately $39.1 million, with up to $4.6 million EBITDA-based contingent consideration and up to $2.3 million employment-contingent consideration.
Credit agreement amended to raise the maximum revolving commitment from $15.0 million to $25.0 million and add the North Carolina subsidiary as a co-borrower.
Company will release earnings November 12, 2026, with a call on November 13, and will address the transaction's impact on 2026 guidance then.
Kustom Entertainment amended its Unit Purchase Agreement to acquire TFL, LLC, extending the outside termination date from October 15, 2026 to December 18, 2026. The amendment also sets expense payment and reimbursement terms for the Sellers, and the closing remains subject to third-party consents, stockholder approvals, and other customary conditions.
Outside termination date moved from October 15, 2026 to December 18, 2026
If the deal does not close by December 18, 2026, Kustom will pay the Sellers' eligible expenses incurred after November 16, 2026
If the agreement is terminated, Kustom will reimburse up to $200,000 of Sellers' costs for an incremental audit within five business days
Ultralife reported third-quarter 2026 sales of $48.3 million, up 11.3% from a year earlier, with GAAP net income of $2.4 million, or $0.14 per share, compared with a loss of $0.07 per share in the 2025 quarter. The company had already agreed on October 27, 2026 to be acquired by EnerSys in an all-cash transaction valued at approximately $320 million, which is expected to close in the first quarter of 2027, so Ultralife will not hold a conference call on the results.
Q3 2026 sales of $48.3 million vs. $43.4 million in Q3 2025; gross margin 27.5% vs. 22.2%
Operating income of $3.2 million vs. an operating loss of $1.0 million a year earlier; GAAP EPS $0.14 vs. ($0.07)
Backlog of $136.0 million at quarter end, up from $117.5 million at the end of Q2 2026
All-cash acquisition by EnerSys (NYSE: ENS) valued at approximately $320 million, including assumed net debt; expected close in Q1 2027
Surgery Partners amended its merger agreement with HealthSpan Partners, an affiliate of Bon Secours Mercy Health, to raise the cash price to $25.00 per share and add monthly ticking fees if the merger does not close by March 1, 2027. The company's board said a rival third-party proposal at $28.00 per share was not a superior proposal, citing longer closing time and regulatory risk, and the company still expects the deal to close in the first quarter of 2027.
Merger consideration increased to $25.00 per share in cash, excluding Bain Capital affiliates' rollover shares
Ticking fee of up to $1.61 per share if the merger closes after March 1, 2027, for a maximum of $26.61 per share at the October 23, 2027 outside date
Company termination fee increased to approximately $149.1 million; expense reimbursement capped at $8.25 million
Board reaffirmed its recommendation; the rival proposal at $28.00 per share was judged not superior, and Bain Capital (about 39% ownership) has agreed to vote in favor
Heron Therapeutics reported third-quarter 2026 net revenue of $35.3 million, down 7.8% from $38.2 million a year earlier, while its net loss narrowed to $5.0 million from $17.5 million. The same day, Heron agreed to sell substantially all of its assets to CorMedix Therapeutics, a deal that requires Heron stockholder approval, and the company is not providing 2026 financial guidance.
Q3 2026 net revenue was $35.3 million, compared with $38.2 million in Q3 2025 and $37.7 million in Q2 2026.
Q3 2026 net loss was $5.0 million, compared with $17.5 million in Q3 2025.
CorMedix Therapeutics will acquire substantially all of Heron's assets under a definitive asset purchase agreement, subject to Heron stockholder approval and other closing conditions.
Heron withdrew its full-year 2026 guidance in August 2026 and is not providing guidance at this time; cash and short-term investments were $23.4 million at September 30, 2026.
The merger between Mentari Therapeutics and InMed Pharmaceuticals closed on November 9, 2026, and the combined company now trades on the Nasdaq Capital Market as MTRI under the name Mentari Therapeutics, Inc. The closing included private placements with about $490 million in gross proceeds, which the company says provide runway into 2029, and the filing puts outstanding shares at about 58.3 million. The filing contains no revenue, profit, or guidance figures, so the financial effect on shareholders is defined mainly by the new capital and share count.
Private financings totaled about $490 million in gross proceeds, led by Fairmount, including conversion of $50.0 million of previously issued convertible notes plus accrued interest.
About 58.3 million shares of common stock and equivalents are outstanding after the reverse stock split, financings, and merger.
Shares began trading on Nasdaq Capital Market under the ticker MTRI on November 9, 2026.
Todd Shegog joined the Board and will chair the Audit Committee.
CNH Industrial agreed to form a joint venture with Kobelco Construction Machinery by selling a 70% interest in its Construction Equipment business for $700 million in cash, based on an agreed enterprise value of $1 billion. CNH will keep a 30% stake and says it expects to use the net cash proceeds to reduce debt, but the deal requires regulatory approvals and is expected to close by the end of 2027.
Buyers pay $700 million in cash for 70% of the business, valued at an enterprise value of $1 billion, subject to adjustments
CNH retains a 30% interest in the joint venture, with a three-year lock-up period for each party
Closing is expected by the end of 2027; either party may terminate if closing has not occurred by March 30, 2028
CNH said it will report its 2026 third quarter earnings in a separate announcement the same day
Quanome agreed on November 4, 2026 to acquire 31,579 newly issued shares of QAI Labs, an early-stage, pre-commercial life sciences company, in exchange for 6,541,236 new Quanome common shares, about 19% of its shares outstanding before the issuance. The parties assigned the consideration shares an aggregate value of $5.0 million, which implies an equity valuation of about $100 million for QAI Labs, and the deal is subject to closing conditions. For shareholders, the deal brings new strategic exposure but also meaningful dilution.
Quanome issues 6,541,236 new common shares, about 19% of shares outstanding before issuance and about 15.97% after.
Quanome receives 31,579 QAI Labs shares, an interest of about 5% immediately after issuance.
Aggregate negotiated transaction value is $5.0 million; implied QAI Labs equity valuation is about $100 million.
The agreement can be terminated if closing has not occurred by December 31, 2026, unless the parties agree otherwise.
Former CEO Dr. Andrew Regan, writing on behalf of Corvus Capital Limited, told the Board in a November 5, 2026 letter that Corvus intends to make a non-binding proposal to acquire all outstanding common stock at $2.00 per share, a 96.3% premium on a post-split basis to the November 4, 2026 closing price, absent a Board proposal. The Board intends to form a special committee of independent directors with full authority over the proposal, but the committee has received no definitive terms and has made no decision, and there is no assurance any transaction will result.
Letter dated November 5, 2026, from Dr. Andrew Regan, former CEO, as a significant stockholder, on behalf of Corvus Capital Limited
Proposed price of $2.00 per share, a 96.3% premium to the November 4, 2026 closing price, on a post-split basis
Board intends to form a special committee of independent directors with full authority to consider and vote on the proposal
No definitive terms received and no decision made; the company does not commit to provide updates
CVR Energy will meet potential lenders on November 9, 2026 about a proposed Term Loan B secured credit facility. The lender presentation describes a potential transaction with Marathon Petroleum Corporation to acquire the St. Paul Park and Mandan refineries and related assets for about $4.2 billion, and it is marked as a preliminary draft, so the deal is not yet final.
Lender meeting scheduled for November 9, 2026 for a proposed Term Loan B secured credit facility
Presentation says the ~$4.2 billion acquisition would be funded with ~$1.5 billion senior secured Term Loan B, ~$1.0 billion of other secured debt, and a mix of equity, cash on hand, crude intermediation and an ABL draw
Target assets are the St. Paul Park, Minnesota and Mandan, North Dakota refineries; pro forma LTM Q3'26 EBITDA is ~$1.9 billion, with an implied acquisition multiple of ~3.6x LTM EBITDA
Company expects ~2.0x LTM Q3'26 Debt/EBITDA after the transaction
On November 8, 2026, CorMedix agreed to acquire substantially all assets of Heron Therapeutics for $145.0 million in cash, 14,583,333 new CorMedix common shares, earn-out payments of up to $55 million, and royalties. CorMedix entered into a $150 million senior secured term loan with Pharmakon Advisors to help fund the deal, with $75 million expected to be drawn at closing. The share issuance will dilute existing CorMedix shareholders, and closing is expected in the first quarter of 2027, subject to Heron stockholder approval and regulatory clearance.
Upfront consideration is $145.0 million in cash, subject to adjustments, plus 14,583,333 shares of CorMedix common stock.
Earn-outs of up to $55 million are tied to 2028 ZYNRELEF net sales, with a 5.0% royalty on certain product sales above $25.0 million a year in 2027 through 2029.
CorMedix entered into a $150 million Pharmakon term loan and expects to draw $75 million at closing.
Closing is expected in the first quarter of 2027, subject to Heron stockholder approval and HSR clearance; Heron owes a $4.0 million termination fee in certain cases.
Heron Therapeutics agreed on November 8, 2026 to sell substantially all of its assets to CorMedix, with Heron keeping its tax loss carryforwards, cash and CorMedix shares, and exiting its current operations. The deal requires Heron stockholder approval and is expected to close in the first quarter of 2027, and shareholders will hold a company that no longer runs its current business.
Upfront consideration of $145.0 million in cash, subject to adjustments, plus 14,583,333 CorMedix common shares
Up to $55 million in earn-out payments tied to 2028 ZYNRELEF net sales, plus a 5% royalty on certain product sales above $25.0 million in 2027 through 2029
Proceeds will repay all amounts outstanding under the Hercules working capital facility, and Rubric's $35.0 million of convertible notes will be exchanged for CorMedix shares
Requires approval by holders of a majority of Heron common stock; $4.0 million termination fee payable in specified circumstances; expected close in the first quarter of 2027
NRG Energy agreed to sell six natural-gas generation assets, totaling 4.9 GW, to an affiliate of LS Power for $4 billion in cash, subject to customary adjustments. The sale is targeted to close in the second quarter of 2027, pending regulatory approvals. NRG plans to use the proceeds for $3 billion of share repurchases across 2026 and 2027 and $2 billion of debt reduction at closing.
Purchase price of $4 billion in cash, subject to working capital and other closing adjustments; implied 2027 valuation of 8.0x EV/Adj. EBITDA
Six assets totaling 4.9 GW: Ravenswood (NYISO), Ocean State Power and Wallingford (ISO-NE), and Jack County, Johnson County and R.W. Miller (ERCOT)
Targeted closing in the second quarter of 2027, subject to HSR, FERC and New York State Public Service Commission approvals
Planned 2027 capital allocation includes $3 billion of share repurchases across 2026 and 2027, with an incremental $1 billion starting before the end of Q4 2026
Abeona Therapeutics acquired APT-1011, now called ABO-801, a clinical-stage treatment candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals in exchange for 4,494,383 common shares valued at $20 million, with no upfront cash. The company also agreed to sell 6,400,000 shares and pre-funded warrants for 1,600,043 shares in a private placement for about $30 million, expected to close November 10, 2026, which will add new shares and dilute existing holders.
Ellodi receives 4,494,383 shares valued at $20 million, based on a 20-day VWAP ending the trading day before the November 6, 2026 closing date, and no upfront cash.
Further payments to Ellodi include $30 million upon FDA approval of a New Drug Application, up to $30 million on sales milestones, and tiered royalties in the low to mid teen percentages.
Private placement of 6,400,000 shares at $3.75 per share plus pre-funded warrants at $3.7499, with Morgan Stanley as sole placement agent and net proceeds for general corporate purposes including ZEVASKYN.
One-third of the upfront shares unlock at each of the 6-, 12- and 18-month anniversaries of closing; resale registration for the private placement shares is due within 15 days after closing.
Charles River Laboratories agreed to acquire the bioanalysis and DMPK operations of Frontage Holdings in Exton, Pennsylvania, for approximately $470 million in cash, plus up to $75 million in performance-based payments. The company expects the deal to be neutral to non-GAAP earnings per share in 2027 and accretive after that, and expects to close in the first half of 2027, subject to shareholder and regulatory approvals.
Purchase price of approximately $470 million in cash, subject to customary closing adjustments, with additional payments of up to $75 million tied to future performance
Acquired businesses represented approximately 40% of Frontage's 2025 revenue of $256.7 million and employ approximately 340 people across two Exton sites
Expected to be neutral to non-GAAP EPS in 2027 and accretive thereafter; to be financed through Charles River's credit facility and available cash
Closing expected in the first half of 2027; Frontage is being taken private by a consortium that includes Tigermed and Dr. Song Li
Pono Capital Four and Blackstar Orbital Technologies signed a First Amendment to their Merger Agreement on November 5, 2026. The amendment lowers the Base Purchase Price used to set the Parent Shares paid to Blackstar securityholders, increases the equity plan share reserve, and extends the outside closing date. The filing says the rest of the Merger Agreement is unchanged, and the Business Combination still requires Pono shareholder approval.
Base Purchase Price reduced from $380,000,000 to $200,000,000, which sets the number of Parent Shares paid to Blackstar securityholders
Parent Shares reserved under the Equity Incentive Plan at Closing increased from 6,000,000 to 7,400,000
Company Outside Closing Date extended from March 31, 2027 to June 30, 2027
Rallybio said the closing of its merger with Avenzo Therapeutics, previously expected on November 6, 2026, has been postponed because certain conditions tied to listing the company's shares after the deal have not been met. The company did not deposit funds for a previously announced cash distribution with Computershare on November 5, 2026, so the payment and ex-dividend dates may be delayed.
Merger closing with Avenzo Therapeutics postponed from the expected November 6, 2026 date while listing approvals are sought
Funds for the cash distribution were not deposited with Computershare on November 5, 2026
Previously announced payment date and ex-dividend date for the cash distribution may be delayed; no new dates given
T3 Defense Inc. completed its acquisition of KeepZone AI Inc. on November 4, 2026, paying by issuing 425,594 shares of common stock to the seller, Nexera Technologies Ltd. An amendment to the purchase agreement raised the purchase price to $1,539,800 and lifted the seller's beneficial ownership limit in the company to 9.9%. The company said the deal was not a significant acquisition, so separate KeepZone financial statements are not required.
Purchase price raised to $1,539,800 under the amendment dated November 4, 2026
425,594 new common shares issued to Nexera Technologies Ltd. as consideration
Seller's beneficial ownership limit in T3 Defense raised to 9.9%
Company states the acquisition was not significant under Item 2.01 of Form 8-K
Kontoor Brands completed the sale of its H.D. Lee Company subsidiary to ABG-Storm LLC, an affiliate of Authentic Brands Group, on November 2, 2026. The company received $750 million in cash at closing, subject to post-closing adjustments, plus up to $250 million in earnout payments tied to the Lee business's performance over five years. The filing says the company anticipates using $400 million for accelerated share repurchases and $50 million for open market repurchases.
Closing date: November 2, 2026; cash at closing of $750 million before post-closing adjustments
Pro forma estimate of cash received after adjustments: approximately $698.2 million
Earnout of up to $250 million over five years; estimated fair value at closing of $77.0 million
Planned use of proceeds: $400 million in accelerated share repurchases and $50 million in open market repurchases
HeartSciences filed an 8-K with supplemental disclosures to its proxy statement for the proposed merger with Fortitude Mining Holdings, a subsidiary of Digital Currency Group. The company received seven demand letters from purported shareholders alleging the proxy omits material information, and says the claims are without merit but is voluntarily adding disclosures to avoid delays and litigation expense. The special meeting remains scheduled for November 19, 2026, so the disclosures do not change the vote timing.
Seven demand letters received from counsel to purported shareholders alleging proxy omissions.
Company denies the allegations and says disclosures are voluntary, made without admitting liability.
Supplemental disclosures include a January 6, 2026 letter of intent with Fortitude and an indicated equity value range for Fortitude of $206.0 million to $428.2 million.
Special Meeting to be held virtually on November 19, 2026, at 10:00 a.m. Eastern Time.
Victory Capital filed an 8-K with supplemental disclosures to its proxy statement for the planned acquisition of First Eagle, which it says it made voluntarily to reduce the risk of litigation delaying the deal. Two stockholder lawsuits and a number of demand letters allege the proxy statement was materially incomplete and misleading, and Victory says those claims are without merit. The company states the supplemental disclosures do not change the consideration or the timing of the November 17, 2026 special meeting.
Base purchase price for First Eagle is $7.03 billion, subject to adjustment, including a reduction for First Eagle's funded debt and other debt-like items.
Share consideration is valued at $2 billion based on $116.26 per share and represents 4.9% of Victory's outstanding common stock after issuance.
Two complaints were filed in New York Supreme Court on October 27 and October 28, 2026, and plaintiffs seek to enjoin the deal or seek rescission or damages.
The special meeting of Victory stockholders is scheduled for November 17, 2026, and the board still recommends voting FOR the proposals.
DTE Energy said it is selling primarily all of its DTE Vantage business for approximately $3 billion to institutional investors advised by J.P. Morgan Asset Management, with closing targeted in the first half of 2027. The company also raised its long-term operating EPS growth target to greater than 9% through 2031, up from a prior 6% to 8% range, and increased its five-year utility capital plan to $44 billion, which it says is nearly 30% above the prior plan.
Transaction value of approximately $3 billion for primarily all DTE Vantage assets, excluding EES Coke and several named custom energy solutions and renewable energy sites
Target closing in the first half of 2027; sale proceeds will be invested in utility businesses, reducing equity and debt needs
Operating EPS growth target of greater than 9% from 2027 to 2031, versus prior 6% to 8% growth profile; 2026 operating EPS guidance of $7.59 to $7.73 remains, with the company positioned to achieve the high end
Average annual equity issuances targeted at about $1 billion from 2027 to 2031; dividend to increase 7% in 2027
Churchill Capital Corp XI (CCXI) completed its business combination with Agility Robotics on November 4, 2026, after shareholders approved it on November 2, 2026. The filing says the aggregate consideration was $2.5 billion and that Agility stockholders will hold about 79.1% of the combined company, so existing CCXI public shareholders will hold a much smaller share. The included unaudited pro forma figures show large net losses and minimal sales, which matter to shareholders assessing the combined company's financial position.
Business combination completed November 4, 2026; aggregate consideration to Agility securityholders was $2,500,000,000.
25,451,804 CCXI Class A shares were redeemed for cash from the trust account; 15,948,196 CCXI public shares remain outstanding in the pro forma table.
Pro forma net loss was $407.7 million for the six months ended June 30, 2026, on net sales of $175 thousand, versus a pro forma net loss of $143.9 million for 2025.
Pro forma cash and cash equivalents were $447.2 million as of June 30, 2026, after the transaction adjustments.
Roku completed its merger with Fox Corporation on November 6, 2026, becoming a wholly owned subsidiary of FOX. Roku stockholders received $95.30 in cash and 0.9799 of a share of FOX Class A common stock per share, and trading of Roku stock on Nasdaq will halt.
The merger became effective on November 6, 2026, resulting in a change in control.
Stockholders are entitled to $95.30 in cash and 0.9799 of a FOX Class A common stock share per share.
Roku requested the removal of its Class A common stock from listing on Nasdaq.
Roku terminated its existing credit agreement dated September 16, 2024.
Bowman Consulting Group Ltd. completed its merger with Prive Parent, Inc., an affiliate of Bernhard Capital Partners, on November 6, 2026, and is now a wholly owned subsidiary of Parent. Each outstanding share was converted into the right to receive $43.00 in cash, so public shareholders no longer hold stock in the company. The company's common stock is being removed from Nasdaq and deregistered, ending its public reporting.
Each share of common stock converted into the right to receive $43.00 in cash, without interest.
The merger was funded by equity commitments from BCP funds and a debt financing commitment, per the filing.
Nasdaq was asked to suspend trading and withdraw the listing before the market opened on November 6, 2026.
Six directors, including founder Gary Bowman, resigned at the Effective Time; Mark D. Spender, Jonathan Parnell, Joe Boyer and Gary Bowman became directors of the Surviving Corporation.
On November 3, 2026, subsidiary The Andersons Renewables, LLC agreed to acquire Harvestone Low Carbon Partners from Energy Capital Partners for $915 million. The three ethanol plants in North Dakota and Indiana have about 215 million gallons of annual capacity, and the company plans to fund the deal with about $300 million from its revolving credit facility and $615 million of new long-term debt. Closing is expected in the fourth quarter of 2026 or early in the first quarter of 2027, subject to regulatory approvals; the company says the deal is expected to be immediately accretive to earnings per share, but the filing gives no figures for this.
Purchase price of $915 million, with about half attributed to expected 45Z and 45Q tax credit cash flows
Three ethanol plants with about 215 million gallons of annual production capacity, combined platform about 730 million gallons
Financing of about $300 million from the revolving credit facility and $615 million in new long-term debt, with committed financing from U.S. Bank and Farm Credit Mid-America
Expected closing in the fourth quarter of 2026 or early in the first quarter of 2027
Acrivon Therapeutics said it acquired Aqilion AB's oral JAK1 inhibitor ACR-525 (formerly AQ280) and a PKCθ inhibitor preclinical program in an asset purchase, paying an undisclosed cash amount. The company says it has no obligation to make milestone or royalty payments, and a separate agreement ends prior royalty and milestone obligations on ACR-525 owed to LEO Pharma. The filing gives no financial results or deal value, so its effect on shareholders is not quantified.
Acrivon paid undisclosed cash consideration with no future milestone or royalty payments owed to Aqilion
Acrivon, Aqilion and LEO Pharma terminated prior royalty and milestone obligations on ACR-525
Eosinophilic esophagitis is the first potential indication for ACR-525, which is described as Phase 2-ready
Acrivon will host a KOL webcast on November 10, 2026, at 4:00 p.m. ET
Sylvamo entered a put option agreement with Midas Atlantic Partners, backed by The Najafi Companies, for a binding offer to acquire its Europe business. The buyer would take the business with an agreed level of working capital and cash, and Sylvamo would receive 20% of future distributions; no purchase price is stated. The company must complete works council and employee consultations before a final decision, and closing is expected by the end of the first quarter of 2027.
Buyer is Midas Atlantic Partners, in partnership with The Najafi Companies
Sylvamo would receive 20% of future distributions from the business in exchange for the transfer
Final decision follows consultations with works councils and employee representatives
Closing is expected by the end of the first quarter of 2027
ANI Pharmaceuticals entered a 364-day senior bridge credit facility of up to $676 million with JPMorgan Chase Bank, N.A. as administrative agent. The facility will be used to finance its recommended public cash offer for Egetis Therapeutics shares, convertible loan and warrants, valued at about SEK 5.6 billion, or approximately $559.9 million, and to refinance ANI's existing term loans and some Egetis debt, which adds significant borrowing and secured obligations for ANI shareholders.
Facility allows borrowings up to $676 million and matures 364 days after initial funding
Initial margin of 1.75% for ABR loans and 2.75% for adjusted term SOFR loans
Offer price is SEK 11.25 per Egetis share; total value about SEK 5.6 billion, or $559.9 million
Completion requires holders of at least 90% of Egetis shares (fully diluted) to tender and regulatory clearances; undertakings covering 42.2% of shares expire if the offer is not declared unconditional by March 31, 2027
iSpecimen completed on November 2, 2026, its acquisition of AI software and related assets from Foldlab AI Ltd. for an aggregate price of $4.5 million, paid in cash, milestone payments and stock. The issuance of 2,907,977 shares to Foldlab on November 5, 2026 gives Foldlab approximately 53.6% of the outstanding common stock, a change in control, which means existing shareholders' ownership is substantially diluted.
Purchase price of $4.5 million: $750,000 cash at closing, two $625,000 milestone payments tied to delivery and acceptance, and $2.5 million in stock.
Stock consideration of 2,907,977 shares, based on a $0.8597 volume-weighted average price, issued to Foldlab on November 5, 2026.
Foldlab holds approximately 53.6% of outstanding shares; Zhengkang (Jacob) Shao is its sole director and shareholder.
Shares are subject to a five-year lock-up with no leak-out; stockholders approved the issuance at a special meeting on October 9, 2026.
NextEra Energy filed unaudited pro forma combined financial information and Dominion Energy's financial statements for the pending merger, which was agreed on May 15, 2026. The filing estimates total merger consideration at $62.1 billion, based on NEE's $83.71 closing price on October 30, 2026, and shows lower pro forma per-share earnings than NEE's historical figures. The deal still requires several regulatory approvals and other closing conditions, and the company says the pro forma figures are illustrative only.
Each Dominion Energy share converts into $360 million in aggregate cash, plus 0.8138 NEE shares, pro rata
Estimated merger consideration is $62.1 billion, based on about 738 million NEE shares at $83.71
Pro forma nine-month 2026 basic EPS is $4.16, versus NEE's historical $4.84
Closing requires HSR clearance and approvals from FERC, NRC, and the Virginia, North Carolina and South Carolina regulators
Axon Enterprise announced an incremental minority investment of about $1.2 billion in drone maker Skydio, which it expects will raise Axon's fully diluted ownership from about 15% to about 37%. The primary purchase closed on November 5, 2026, and the remaining transactions are expected to close in the fourth quarter of 2026 and first quarter of 2027. The deal adds a large cash outlay and share issuance for Axon, and Axon also becomes Skydio's exclusive public safety distributor in the U.S. and Canada.
Primary purchase closed November 5, 2026: 25,000,000 Series G preferred shares at $10.19617 per share, for about $254.9 million in aggregate.
Total investment is about $1.2 billion, with about $720 million (approximately 60%) expected in cash and the remainder in Axon common stock.
Axon stock issued for the investment is capped at 19.99% of shares outstanding before the primary closing.
Tender offer to begin within ten business days of the primary closing; the Committed Secondary is expected to close in the first quarter of 2027.
Sunrise Realty Trust (SUNS) completed its merger with Southern Realty Trust on November 5, 2026. Southern Realty Trust stockholders received 1.45 SUNS shares and $0.05 in cash from SUNS Manager for each share they held, and SUNS issued 8,464,975 shares, bringing shares outstanding to 21,980,826. The company also amended its management agreement, cutting the incentive fee and hurdle rate and reducing the base management fee, which the filing says benefits all SUNS stockholders, while former Southern Realty Trust holders now own about 38.5% of the combined company.
Merger closed November 5, 2026; each Southern Realty Trust share converted into 1.45 SUNS shares plus $0.05 in cash from SUNS Manager
SUNS issued 8,464,975 shares, resulting in 21,980,826 shares outstanding; former Southern Realty Trust stockholders own about 38.5%
Incentive fee reduced from 20% to 17.5% and hurdle rate from 8.0% to 7.0%; base management fee cut by $250,000 per quarter for four quarters, or $1.0 million in total
Pro forma as of June 30, 2026, the combined company had about $534 million of total assets and about $285 million of book value
On November 2, 2026, American Water, Essential Utilities and certain affiliates filed a Stipulation of Settlement in the New Jersey Board of Public Utilities proceeding on their proposed merger. The stipulation was entered into with all parties, including NJBPU staff and the New Jersey Division of Rate Counsel, and was posted to the NJBPU website as of November 5, 2026. It remains subject to review and approval by the NJBPU, and the filing does not describe the settlement terms.
Merger Agreement with Essential Utilities entered into October 26, 2025, with Essential Utilities surviving as a wholly owned subsidiary of American Water
Stipulation of Settlement filed in the NJBPU proceeding on November 2, 2026, with all parties, including NJBPU staff and the New Jersey Division of Rate Counsel
Stipulation posted to the NJBPU website as of November 5, 2026, and subject to NJBPU review and approval
Pacira BioSciences said Viatris has commenced a tender offer to buy all Pacira shares for $36.50 each in cash, under a merger agreement signed October 8, 2026, with a second-step merger planned after the offer closes. Pacira will not issue its Q3 2026 earnings release or hold a call, and it has withdrawn its 2026 financial guidance, so shareholders will have no updated company financial outlook during the pending deal.
Viatris, through subsidiary Peach Purchaser Sub Inc., commenced the tender offer on October 30, 2026 at $36.50 per share in cash
Merger agreement with Viatris was entered into on October 8, 2026; completion depends on conditions including a Minimum Condition
Pacira will not release Q3 results for the quarter ended September 30, 2026, and has withdrawn its previously issued 2026 guidance
Drilling Tools International furnished an investor presentation under Regulation FD that reaffirms its 2026 revenue and Adjusted EBITDA outlook and revises its capital expenditure and Adjusted Free Cash Flow outlook. The deck also details the pending Saltire Energy acquisition, which would be paid for with about $80 million in cash and 17.4 million DTI shares and requires DTI stockholder approval.
Q3 2026 revenue was $40.6 million and Adjusted EBITDA was $9.5 million, which the company says increased sequentially.
2026 guidance reaffirmed: revenue of $155 million to $170 million and Adjusted EBITDA of $35 million to $45 million.
Saltire consideration is about $80 million in cash plus 17.4 million DTI shares, with Saltire run-rate Adjusted EBITDA of $22.5 million and expected closing in Q1 2027.
PSQ Holdings closed the sale of its EveryLife direct-to-consumer baby products business to FreeHold Brands on November 5, 2026, for total consideration of $5.5 million, subject to customary adjustments. The company says the sale completes its move to a focused payments and consumer financing business, with proceeds intended to strengthen the balance sheet and fund growth.
Consideration: $1.0 million in cash at closing plus a $4.5 million seller note secured by EveryLife assets
Seller note accrues interest at the prime rate from February 1, 2027, with a minimum monthly principal payment of $83,333
Note matures 12 months after closing, with up to two 12-month extensions if the buyer cannot obtain bank financing
Company states it now operates exclusively in payments and consumer financing
Essential Utilities filed an 8-K furnishing American Water's unaudited financial statements for the quarter and nine months ended September 30, 2026, as Exhibit 99.1. The filing is tied to the pending merger under which Essential would become a wholly owned subsidiary of American Water, and the merger has not yet closed.
American Water third-quarter 2026 operating revenues were $1,510 million, up from $1,451 million a year earlier.
Third-quarter net income attributable to common shareholders was $387 million, compared with $379 million, with diluted EPS of $1.94 in both periods.
Nine-month diluted EPS was $4.56 versus $4.47, and the merger remains subject to customary closing conditions, including regulatory approvals.
LightPath Technologies closed the sale of its wholly owned Chinese subsidiary, LightPath (Zhenjiang) Optical Instrumentation Co., Ltd., effective October 30, 2026, to an entity owned by the subsidiary's incumbent management team. The company says it no longer has any facilities or operations in China, and the former subsidiary will continue to supply products to its U.S. and European commercial customers as a third-party vendor.
Sale closed effective October 30, 2026; LightPath sold 100% of its interest in LPOIZ.
Buyer is an entity owned by LPOIZ's incumbent management team.
China operation's third-party revenue averaged approximately $4.5 million annually across fiscal years 2025 and 2026 and will no longer be consolidated.
LPOIZ will continue to supply LightPath's commercial customers in the U.S. and Europe as a third-party vendor.
Five9 entered into a merger agreement on November 5, 2026, to acquire Level AI, with Level AI becoming a wholly owned subsidiary. The cash price is $325.0 million, subject to customary adjustments, and the company says the deal adds AI capabilities and a new way to reach enterprises. Completion depends on customary closing conditions, and the deal is expected to close in 2026.
Aggregate consideration is $325.0 million in cash, subject to adjustments for Level AI's cash, indebtedness, transaction expenses and net working capital at closing.
Stockholders of Level AI holding enough voting power to approve the deal have signed support agreements, so no further Level AI stockholder approval is required.
Either party may terminate if closing has not occurred by February 5, 2027; neither party must pay a termination fee.
Five9 says the deal is expected to close in 2026, and Centerview Partners LLC is its financial advisor.
Willdan Group completed its acquisition of Mantis Intermediate Holdings, LLC, doing business as Mantis Innovation, on October 30, 2026, for approximately $285 million, subject to post-closing adjustments. The company funded the price with $35.0 million from its revolving credit facility and $250.0 million from a new term loan, and said it will provide updated financial guidance on its third quarter earnings call scheduled for November 5, 2026.
Purchase price of approximately $285 million, subject to customary post-closing adjustments, closed October 30, 2026
Funding: $35.0 million of revolving credit facility borrowings and $250.0 million under a new term loan
New $250.0 million term loan matures May 5, 2030, with terms identical to existing credit facilities
Updated financial guidance to be discussed on the November 5, 2026 third quarter earnings call
Armada Acquisition Corp. III, a special purpose acquisition company, signed a business combination agreement on October 31, 2026 with Brains Bioceutical Corp., a Vancouver-based maker of cannabinoid active pharmaceutical ingredients and drug developer. The deal values Brains at an implied pre-money equity value of approximately $750.0 million, and the combined company is expected to trade on Nasdaq as BAPI, with closing expected in the second quarter of 2027 subject to shareholder and regulatory approvals.
Enterprise value of $750.0 million, with new PubCo shares priced at a $10.20 reference value per share
14,705,882 additional earnout shares held in escrow, released if PubCo shares reach $12.50 or $15.00 volume-weighted average price over a three-year earnout period
Closing expected in the second quarter of 2027, subject to shareholder votes, Form F-4 registration effectiveness, Nasdaq listing approval and regulatory approvals
Combined company expected to be named Brains Therapeutics Corp. and trade on Nasdaq under the ticker BAPI
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.